Health economics evaluation of gastric cancer prevention and screening: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

QIN Shuxia ¹ , YI Lidan ¹ , LI Sini ^2,3 , WU Meiyu ¹ , WANG Liting ¹ , ZENG Xiaohui ⁴ , TAN Chongqing ¹ , PENG Liubao ¹ ,  WAN Xiaomin ¹

1. Department of Pharmacy, the Second Xiangya Hospital of Central South University, Changsha 410011, P. R. China;
2. Xiangya Nursing School, Central South University, Changsha 410013, P. R. China;
3. School of Health and Related Research, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield S1 2LB, United Kingdom;
4. PET CT Center, the Second Xiangya Hospital of Central South University, Changsha 410011, P. R. China;

Corresponding?author：

WAN Xiaomin, Email: wanxiaomin@csu.edu.cn

Keywords：

Stomach cancer; Screening; Health economics; Systematic review

DOI：

10.7507/1672-2531.202201007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the current situation of health economics evaluation of gastric cancer screening. Methods The PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data and VIP databases were electronically searched to collect the health economics evaluation studies on gastric cancer screening from January 1^st, 1975 to September 30^th, 2021. Two reviewers independently screened the literature, extracted data and assessed the risk of bias of the included studies. Then, qualitative analysis was performed. Results A total of 44 studies were included. Most of the targeted populations of the study were high-risk groups in areas with a high incidence of gastric cancer. Screening methods such as endoscopy and Helicobacter pylori infection detection were mainly evaluated in those studies. According to the results, about 47% of the studies evaluated a single screening method. A total of 35 studies showed that they established models, however, only a few calibrated the models. Conclusion Most studies of gastric cancer screening reviews neither calibrate the results nor consider the effect of smoking on the progression of gastric cancer. Those evaluated screening programs are limited.

Citation： QIN Shuxia, YI Lidan, LI Sini, WU Meiyu, WANG Liting, ZENG Xiaohui, TAN Chongqing, PENG Liubao, WAN Xiaomin. Health economics evaluation of gastric cancer prevention and screening: a systematic review. Chinese Journal of Evidence-Based Medicine, 2022, 22(7): 812-821. doi: 10.7507/1672-2531.202201007 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	International Agency for Research on Cancer. Global cancer observatory: cancer today, 2021-09-24. Available at: https://gco.iarc.fr/today..
3.	劉宗超, 李哲軒, 張陽, 等. 2020全球癌癥統計報告解讀. 腫瘤綜合治療電子雜志, 2021, 7(2): 1-13.
4.	Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100 000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer, 2018, 21(1): 144-154.
5.	Spratt JS. The primary and secondary prevention of cancer. J Surg Oncol, 1981, 18(3): 219-230.
6.	IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum, 1994, 61: 1-241.
7.	Guo Y, Li ZX, Zhang JY, et al. Association between lifestyle factors, vitamin and garlic supplementation, and gastric cancer outcomes: a secondary analysis of a randomized clinical trial. JAMA Netw Open, 2020, 3(6): e206628.
8.	Asaka M, Sugiyama T, Nobuta A, et al. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter, 2001, 6(4): 294-299.
9.	Zhou L, Lin S, Ding S, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chin Med J (Engl), 2014, 127(8): 1454-1458.
10.	Hojo M, Miwa H, Ohkusa T, et al. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther, 2002, 16(11): 1923-1932.
11.	Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut, 2020, 69(12): 2093-2112.
12.	Chen R, Liu Y, Song G, et al. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study. Gut, 2021, 70(2): 251-260.
13.	Hamashima C, Ogoshi K, Okamoto M, et al. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One, 2013, 8(11): e79088.
14.	Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology, 2017, 152(6): 1319-1328.
15.	Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes (4th ed). Oxford: Oxford University Press, 2015.
16.	Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet, 1996, 348(9021): 150-154.
17.	Leivo T, Salomaa A, Kosunen TU, et al. Cost-benefit analysis of Helicobacter pylori screening. Health Policy, 2004, 70(1): 85-96.
18.	Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer, 2009, 124(1): 157-166.
19.	Kowada A. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan. Epidemiol Infect, 2018, 146(14): 1834-1840.
20.	Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med, 1999, 159(2): 142-148.
21.	Harris RA, Owens DK, Witherell H, et al. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter, 1999, 4(2): 69-76.
22.	李存艷, 張開金. 芬蘭幽門螺旋桿菌篩查成本-效益分析. 國外醫學(衛生經濟分冊), 2007, (4): 184-191.
23.	王倩, 林果為, 金丕煥, 等. 篩查幽門螺桿菌預防胃癌的Markov模型衛生經濟學評價. 中華流行病學雜志, 2003, (2): 57-61.
24.	Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci, 2002, 5(4): 249-258.
25.	Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther, 2002, 16(3): 559-568.
26.	Chen Q, Liang X, Long X, et al. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter, 2019, 24(2): e12563.
27.	H?gh MB, Kronborg C, Hansen JM, et al. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther, 2019, 49(8): 1013-1025.
28.	Han Y, Yan T, Ma H, et al. Cost-effectiveness analysis of helicobacter pylori eradication therapy for prevention of gastric cancer: a Markov model. Dig Dis Sci, 2020, 65(6): 1679-1688.
29.	Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen, 2003, 10(3): 148-156.
30.	陳琦, 方穎, 梁曉, 等. 中國自然人群篩查與伺機性檢測策略預防幽門螺桿菌相關疾病的衛生經濟學評價. 中華消化雜志, 2021, 41(4): 234-240.
31.	Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev, 2007, 16(5): 875-885.
32.	Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model. World J Gastroenterol, 2008, 14(19): 3021-3027.
33.	Xie F, Luo N, Blackhouse G, et al. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care, 2008, 24(1): 87-95.
34.	Xie F, O'Reilly D, Ferrusi IL, et al. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol, 2009, 6(5): 317-323.
35.	Schulz TR, McBryde ES, Leder K, et al. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One, 2014, 9(9): e108610.
36.	Teng AM, Kvizhinadze G, Nair N, et al. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis, 2017, 17(1): 156.
37.	Kowada A. Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries. Scand J Gastroenterol, 2019, 54(6): 685-689.
38.	Saito S, Azumi M, Muneoka Y, et al. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ, 2018, 19(4): 545-555.
39.	Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut, 2016, 65(4): 563-574.
40.	Zhou L, Guan P, Sun LP, et al. Health economic assessment for screening of gastric cancer in a high risk population in northeastern china. Chin J Cancer Res, 2011, 23(1): 21-24.
41.	Areia M, Spaander MC, Kuipers EJ, et al. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J, 2018, 6(2): 192-202.
42.	Tsuji I, Fukao A, Sugawara N, et al. Cost-effectiveness analysis of screening for gastric cancer in Japan. Tohoku J Exp Med, 1991, 164(4): 279-284.
43.	Babazono A, Hillman AL. Declining cost-effectiveness of screening for disease. The case of gastric cancer in Japan. Int J Technol Assess Health Care, 1995, 11(2): 354-364.
44.	Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol, 2006, 12(30): 4873-4874.
45.	Lee HY, Park EC, Jun JK, et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol, 2010, 16(2): 245-250.
46.	Chang HS, Park EC, Chung W, et al. Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev, 2012, 13(6): 2721-2728.
47.	Cho E, Kang MH, Choi KS, et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev, 2013, 14(4): 2533-2540.
48.	Suh YS, Lee J, Woo H, et al. National cancer screening program for gastric cancer in Korea: Nationwide treatment benefit and cost. Cancer, 2020, 126(9): 1929-1939.
49.	Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol, 2006, 4(6): 709-716.
50.	Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc, 2011, 74(3): 610-624.
51.	Shah SC, Canakis A, Peek RM, et al. Endoscopy for gastric cancer screening is cost effective for Asian Americans in the United States. Clin Gastroenterol Hepatol, 2020, 18(13): 3026-3039.
52.	Huang HL, Leung CY, Saito E, et al. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Med, 2020, 18(1): 257.
53.	Ascherman B, Oh A, Hur C. International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk. Gastric Cancer, 2021, 24(4): 878-887.
54.	Kowada A. Endoscopy is cost-effective for gastric cancer screening after successful helicobacter pylori eradication. Dig Dis Sci, 2021, 66(12): 4220-4226.
55.	Xia R, Zeng H, Liu W, et al. Estimated cost-effectiveness of endoscopic screening for upper gastrointestinal tract cancer in high-risk areas in China. JAMA Netw Open, 2021, 4(8): e2121403.
56.	朱玫燁, 薛佳殷, 李萍, 等. 胃癌高危人群胃鏡監測策略的衛生經濟學評價. 中國衛生統計, 2017, 34(3): 462-464.
57.	丁士剛, 王覺生, 林三仁, 等. 胃癌序貫篩查法實施后的費用—效果分析. 中國腫瘤臨床與康復, 2000, (2): 46-48.
58.	張麗, 沈理, 陸殿元, 等. 口服超聲造影聯合胃鏡篩查胃癌衛生經濟學評價初步報告. 外科理論與實踐, 2014, 19(5): 464-466.
59.	Kapoor R, So JBY, Zhu F, et al. Evaluating the use of microRNA blood tests for gastric cancer screening in a stratified population-level screening program: an early model-based cost-effectiveness analysis. Value Health, 2020, 23(9): 1171-1179.
60.	Balakrishnan M, George R, Sharma A, et al. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep, 2017, 19(8): 36.
61.	Goto R, Hamashima C, Mun S, et al. Why screening rates vary between Korea and Japan-differences between two national healthcare systems. Asian Pac J Cancer Prev, 2015, 16(2): 395-400.
62.	Hamashima C,. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol, 2018, 48(7): 673-683.
63.	Choi KS, Kwak MS, Lee HY, et al. Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev, 2009, 18(5): 1390-1398.
64.	國家消化系疾病臨床醫學研究中心, 中華醫學會消化內鏡學分會, 中華醫學會健康管理學分會, 等. 中國早期胃癌篩查流程專家共識意見(草案2017年, 上海). 中華消化內鏡雜志, 2018, 35(2): 77-83.
65.	Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, 2001, 49(3): 347-353.
66.	Kneller RW, You WC, Chang YS, et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst, 1992, 84(16): 1261-1266.
67.	Praud D, Rota M, Pelucchi C, et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. Eur J Cancer Prev, 2018, 27(2): 124-133.
68.	Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control, 2008, 19(7): 689-701.
69.	Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol, 2008, 103(3): 510-514.
70.	Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017, 66(1): 6-30.
71.	Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn, 1987, 22(2): 133-141.
72.	Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut, 2005, 54(6): 764-768.
73.	朱春平, 趙建業, 申曉軍, 等. 血清胃泌素-17聯合胃蛋白酶原檢測對胃癌診斷價值的多中心臨床研究. 中華消化內鏡雜志, 2017, 34(1): 19-23.
74.	Shiotani A, Iishi H, Uedo N, et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer, 2005, 115(3): 463-469.
75.	Xie Y, Shi L, He X, et al. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf), 2021, 9(2): 91-104.
76.	Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet, 1975, 2(7924): 58-60.
77.	Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics, 2011, 29(1): 35-49.
78.	van Luijt PA, Heijnsdijk EA, de Koning HJ. Cost-effectiveness of the Norwegian breast cancer screening program. Int J Cancer, 2017, 140(4): 833-840.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. International Agency for Research on Cancer. Global cancer observatory: cancer today, 2021-09-24. Available at: https://gco.iarc.fr/today..
3. 劉宗超, 李哲軒, 張陽, 等. 2020全球癌癥統計報告解讀. 腫瘤綜合治療電子雜志, 2021, 7(2): 1-13.
4. Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100 000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer, 2018, 21(1): 144-154.
5. Spratt JS. The primary and secondary prevention of cancer. J Surg Oncol, 1981, 18(3): 219-230.
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum, 1994, 61: 1-241.
7. Guo Y, Li ZX, Zhang JY, et al. Association between lifestyle factors, vitamin and garlic supplementation, and gastric cancer outcomes: a secondary analysis of a randomized clinical trial. JAMA Netw Open, 2020, 3(6): e206628.
8. Asaka M, Sugiyama T, Nobuta A, et al. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter, 2001, 6(4): 294-299.
9. Zhou L, Lin S, Ding S, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chin Med J (Engl), 2014, 127(8): 1454-1458.
10. Hojo M, Miwa H, Ohkusa T, et al. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther, 2002, 16(11): 1923-1932.
11. Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut, 2020, 69(12): 2093-2112.
12. Chen R, Liu Y, Song G, et al. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study. Gut, 2021, 70(2): 251-260.
13. Hamashima C, Ogoshi K, Okamoto M, et al. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One, 2013, 8(11): e79088.
14. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology, 2017, 152(6): 1319-1328.
15. Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes (4th ed). Oxford: Oxford University Press, 2015.
16. Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet, 1996, 348(9021): 150-154.
17. Leivo T, Salomaa A, Kosunen TU, et al. Cost-benefit analysis of Helicobacter pylori screening. Health Policy, 2004, 70(1): 85-96.
18. Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer, 2009, 124(1): 157-166.
19. Kowada A. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan. Epidemiol Infect, 2018, 146(14): 1834-1840.
20. Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med, 1999, 159(2): 142-148.
21. Harris RA, Owens DK, Witherell H, et al. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter, 1999, 4(2): 69-76.
22. 李存艷, 張開金. 芬蘭幽門螺旋桿菌篩查成本-效益分析. 國外醫學(衛生經濟分冊), 2007, (4): 184-191.
23. 王倩, 林果為, 金丕煥, 等. 篩查幽門螺桿菌預防胃癌的Markov模型衛生經濟學評價. 中華流行病學雜志, 2003, (2): 57-61.
24. Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci, 2002, 5(4): 249-258.
25. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther, 2002, 16(3): 559-568.
26. Chen Q, Liang X, Long X, et al. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter, 2019, 24(2): e12563.
27. H?gh MB, Kronborg C, Hansen JM, et al. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther, 2019, 49(8): 1013-1025.
28. Han Y, Yan T, Ma H, et al. Cost-effectiveness analysis of helicobacter pylori eradication therapy for prevention of gastric cancer: a Markov model. Dig Dis Sci, 2020, 65(6): 1679-1688.
29. Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen, 2003, 10(3): 148-156.
30. 陳琦, 方穎, 梁曉, 等. 中國自然人群篩查與伺機性檢測策略預防幽門螺桿菌相關疾病的衛生經濟學評價. 中華消化雜志, 2021, 41(4): 234-240.
31. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev, 2007, 16(5): 875-885.
32. Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model. World J Gastroenterol, 2008, 14(19): 3021-3027.
33. Xie F, Luo N, Blackhouse G, et al. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care, 2008, 24(1): 87-95.
34. Xie F, O'Reilly D, Ferrusi IL, et al. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol, 2009, 6(5): 317-323.
35. Schulz TR, McBryde ES, Leder K, et al. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One, 2014, 9(9): e108610.
36. Teng AM, Kvizhinadze G, Nair N, et al. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis, 2017, 17(1): 156.
37. Kowada A. Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries. Scand J Gastroenterol, 2019, 54(6): 685-689.
38. Saito S, Azumi M, Muneoka Y, et al. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ, 2018, 19(4): 545-555.
39. Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut, 2016, 65(4): 563-574.
40. Zhou L, Guan P, Sun LP, et al. Health economic assessment for screening of gastric cancer in a high risk population in northeastern china. Chin J Cancer Res, 2011, 23(1): 21-24.
41. Areia M, Spaander MC, Kuipers EJ, et al. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J, 2018, 6(2): 192-202.
42. Tsuji I, Fukao A, Sugawara N, et al. Cost-effectiveness analysis of screening for gastric cancer in Japan. Tohoku J Exp Med, 1991, 164(4): 279-284.
43. Babazono A, Hillman AL. Declining cost-effectiveness of screening for disease. The case of gastric cancer in Japan. Int J Technol Assess Health Care, 1995, 11(2): 354-364.
44. Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol, 2006, 12(30): 4873-4874.
45. Lee HY, Park EC, Jun JK, et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol, 2010, 16(2): 245-250.
46. Chang HS, Park EC, Chung W, et al. Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev, 2012, 13(6): 2721-2728.
47. Cho E, Kang MH, Choi KS, et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev, 2013, 14(4): 2533-2540.
48. Suh YS, Lee J, Woo H, et al. National cancer screening program for gastric cancer in Korea: Nationwide treatment benefit and cost. Cancer, 2020, 126(9): 1929-1939.
49. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol, 2006, 4(6): 709-716.
50. Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc, 2011, 74(3): 610-624.
51. Shah SC, Canakis A, Peek RM, et al. Endoscopy for gastric cancer screening is cost effective for Asian Americans in the United States. Clin Gastroenterol Hepatol, 2020, 18(13): 3026-3039.
52. Huang HL, Leung CY, Saito E, et al. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Med, 2020, 18(1): 257.
53. Ascherman B, Oh A, Hur C. International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk. Gastric Cancer, 2021, 24(4): 878-887.
54. Kowada A. Endoscopy is cost-effective for gastric cancer screening after successful helicobacter pylori eradication. Dig Dis Sci, 2021, 66(12): 4220-4226.
55. Xia R, Zeng H, Liu W, et al. Estimated cost-effectiveness of endoscopic screening for upper gastrointestinal tract cancer in high-risk areas in China. JAMA Netw Open, 2021, 4(8): e2121403.
56. 朱玫燁, 薛佳殷, 李萍, 等. 胃癌高危人群胃鏡監測策略的衛生經濟學評價. 中國衛生統計, 2017, 34(3): 462-464.
57. 丁士剛, 王覺生, 林三仁, 等. 胃癌序貫篩查法實施后的費用—效果分析. 中國腫瘤臨床與康復, 2000, (2): 46-48.
58. 張麗, 沈理, 陸殿元, 等. 口服超聲造影聯合胃鏡篩查胃癌衛生經濟學評價初步報告. 外科理論與實踐, 2014, 19(5): 464-466.
59. Kapoor R, So JBY, Zhu F, et al. Evaluating the use of microRNA blood tests for gastric cancer screening in a stratified population-level screening program: an early model-based cost-effectiveness analysis. Value Health, 2020, 23(9): 1171-1179.
60. Balakrishnan M, George R, Sharma A, et al. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep, 2017, 19(8): 36.
61. Goto R, Hamashima C, Mun S, et al. Why screening rates vary between Korea and Japan-differences between two national healthcare systems. Asian Pac J Cancer Prev, 2015, 16(2): 395-400.
62. Hamashima C,. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol, 2018, 48(7): 673-683.
63. Choi KS, Kwak MS, Lee HY, et al. Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev, 2009, 18(5): 1390-1398.
64. 國家消化系疾病臨床醫學研究中心, 中華醫學會消化內鏡學分會, 中華醫學會健康管理學分會, 等. 中國早期胃癌篩查流程專家共識意見(草案2017年, 上海). 中華消化內鏡雜志, 2018, 35(2): 77-83.
65. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, 2001, 49(3): 347-353.
66. Kneller RW, You WC, Chang YS, et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst, 1992, 84(16): 1261-1266.
67. Praud D, Rota M, Pelucchi C, et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. Eur J Cancer Prev, 2018, 27(2): 124-133.
68. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control, 2008, 19(7): 689-701.
69. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol, 2008, 103(3): 510-514.
70. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017, 66(1): 6-30.
71. Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn, 1987, 22(2): 133-141.
72. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut, 2005, 54(6): 764-768.
73. 朱春平, 趙建業, 申曉軍, 等. 血清胃泌素-17聯合胃蛋白酶原檢測對胃癌診斷價值的多中心臨床研究. 中華消化內鏡雜志, 2017, 34(1): 19-23.
74. Shiotani A, Iishi H, Uedo N, et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer, 2005, 115(3): 463-469.
75. Xie Y, Shi L, He X, et al. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf), 2021, 9(2): 91-104.
76. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet, 1975, 2(7924): 58-60.
77. Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics, 2011, 29(1): 35-49.
78. van Luijt PA, Heijnsdijk EA, de Koning HJ. Cost-effectiveness of the Norwegian breast cancer screening program. Int J Cancer, 2017, 140(4): 833-840.

Chinese Journal of Evidence-Based Medicine

Health economics evaluation of gastric cancer prevention and screening: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content